Jingxian Chen
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Clinical Significance of Reduced Forced Expiratory Volume in 3 Seconds to Forced Expiratory Volume in 6 Seconds in Adults.
Journal: Chronic obstructive pulmonary diseases (Miami, Fla.)
Published: April 08, 2026
Association of forced expiratory volume in 0.5 seconds/forced vital capacity ratio with all-cause mortality in adults: a cohort study.
Journal: Journal of thoracic disease
Published: February 15, 2025
Association between FEV1/FVC levels and all-cause mortality in the general population.
Journal: BMC pulmonary medicine
Published: December 16, 2024
Association of Forced Expiratory Volume in 0.5s With All-Cause Mortality Risk in Adults.
Journal: Archivos de bronconeumologia
Published: September 24, 2024
Membranolytic peptide programs immunogenic cell death for cancer therapy.
Journal: Nature
Published: March 19, 2024
Real-world effectiveness of GLP-1 receptor agonist-based treatment strategies on "time in range" in patients with type 2 diabetes.
Journal: Frontiers in pharmacology
Published: January 15, 2024
Relationship between gut microbiota and the pathogenesis of gestational diabetes mellitus: a systematic review.
Journal: Frontiers in cellular and infection microbiology
Published: January 02, 2024
Epidemiological Analysis of Global and Regional Lung Cancer Mortality: Based on 30-Year Data Analysis of Global Burden Disease Database.
Journal: Healthcare (Basel, Switzerland)
Published: September 09, 2023
The global, regional and national burden of type 2 diabetes mellitus in the past, present and future: a systematic analysis of the Global Burden of Disease Study 2019.
Journal: Frontiers in endocrinology
Published: March 23, 2023
Editorial: Role of gut microbiota in diabetes mellitus and tumor immunity.
Journal: Frontiers in immunology
Published: March 13, 2023
Efficacy of polyethylene glycol loxenatide versus insulin glargine on glycemic control in patients with type 2 diabetes: a randomized, open-label, parallel-group trial.
Journal: Frontiers in pharmacology
Published: February 22, 2023
Last Updated: 09/26/2026